Christina Athanasiou

Christina Athanasiou

Auto-generated profile, based on publicly available information

Christina Athanasiou

Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS)

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HLHari Leontiadou
Hari Leontiadou
IGIoannis Galdadas
Ioannis Galdadas
CAChristina Athanasiou
Christina Athanasiou
ZCZoe Cournia
Zoe Cournia
Phosphoinositide 3-kinase alpha (PI3Kα) is involved in fundamental cellular processes including cell proliferation and differentiation and is frequently mutated in human malignancies. One of the most common mutations is E545K, which results in an amino acid substitution of opposite charge. It has been recently proposed that in this oncogenic charge-reversal mutation, the interactions between the protein catalytic and regulatory subunits are abrogated, resulting in loss of regulation and constitutive PI3Kα activity, which can lead to oncogenesis. To assess the mechanism of the PI3Kα E545K activating mutation, extensive Molecular Dynamics simulations were performed to examine conformational changes differing between the wild type (WT) and mutant proteins as they occur in microsecond simulations. In the E545K mutant PI3Kα, we observe a spontaneous detachment of the nSH2 PI3Kα domain (regulatory subunit, p85α) from the helical domain (catalytic subunit, p110α) causing significant loss of communication between the regulatory and catalytic subunits. We examine the allosteric network of the two proteins and show that a cluster of residues around the mutation is important for delivering communication signals between the catalytic and regulatory subunits. Our results demonstrate the dynamical and structural effects induced by the p110α E545K mutation in atomic level detail and indicate a possible mechanism for the loss of regulation that E545K confers on PI3Kα.

23 February 2023 in Journal of Chemical Theory and Computation
Verified
Journal Article
Closed access
ACAinara Claveras Cabezudo
Ainara Claveras Cabezudo
CAChristina Athanasiou
Christina Athanasiou
ATAlexandros Tsengenes
Alexandros Tsengenes
Rebecca WadeRebecca Wade
Rebecca Wade

8 November 2017 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
CAChristina Athanasiou
Christina Athanasiou
SVsofia vasilakaki
sofia vasilakaki
DDDimitris Dellis
Dimitris Dellis
ZCZoe Cournia
Zoe Cournia

6 March 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
TRThanasis Rogdakis
Thanasis Rogdakis
DCDespoina Charou
Despoina Charou
Alessia LatorrataAlessia Latorrata
Alessia Latorrata
EPEleni Papadimitriou
Eleni Papadimitriou
ATAlexandros Tsengenes
Alexandros Tsengenes
Ioannis CharalampopoulosIoannis Charalampopoulos
Ioannis Charalampopoulos
Neurotrophins are growth factors that exert important neuroprotective effects by preventing neuronal death and synaptic loss. Nerve Growth Factor (NGF) acts through the activation of its high-affinity, pro-survival TrkA and low-affinity, pro-apoptotic p75NTR receptors. NGF has been shown to slow or prevent neurodegenerative signals in Alzheimer’s Disease (AD) progression. However, its low bioavailability and its blood–brain-barrier impermeability limit the use of NGF as a potential therapeutic agent against AD. Based on our previous findings on synthetic dehydroepiandrosterone derivatives, we identified a novel NGF mimetic, named ENT-A013, which selectively activates TrkA and exerts neuroprotective, anti-amyloid-β actions. We now report the chemical synthesis, in silico modelling, metabolic stability, CYP-mediated reaction phenotyping and biological characterization of ENT-A013 under physiological and neurodegenerative conditions. We show that ENT-A013 selectively activates the TrkA receptor and its downstream kinases Akt and Erk1/2 in PC12 cells, protecting these cells from serum deprivation-induced cell death. Moreover, ENT-A013 promotes survival of primary Dorsal Root Ganglion (DRG) neurons upon NGF withdrawal and protects hippocampal neurons against Amyloid β-induced apoptosis and synaptic loss. Furthermore, this neurotrophin mimetic partially restores LTP impairment. In conclusion, ENT-A013 represents a promising new lead molecule for developing therapeutics against neurodegenerative disorders, such as Alzheimer’s Disease, selectively targeting TrkA-mediated pro-survival signals.

11 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAinara Claveras Cabezudo
Ainara Claveras Cabezudo
CAChristina Athanasiou
Christina Athanasiou
ATAlexandros Tsengenes
Alexandros Tsengenes
Rebecca WadeRebecca Wade
Rebecca Wade
Martini 3, the latest version of the widely used Martini force field for coarse-grained molecular dynamics simulations, is a promising tool to investigate proteins in phospholipid bilayers. However, simulating other lipid environments, such as detergent micelles, presents challenges due to the absence of validated parameters for their constituent molecules. Here, we propose parameters for the micelle-forming surfactant, dodecylphosphocholine (DPC). These result in micelle assembly with aggregation numbers in agreement with experimental values. However, we identified a lack of hydrophobic interactions between transmembrane helix protein dimers and the tails of DPC molecules, preventing insertion and stabilization of the protein in the micelles. This problem was also observed for protein insertion by self-assembling 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) or dipalmitoylphosphatidylcholine (DPPC) bilayers. We propose the reduction of the non-bonded interactions between protein and water beads by 10% as a simple and effective solution to this problem that enables protein encapsulation in phospholipid micelles and bilayers without altering protein dimerization or bilayer structure. Abstract Figure:

7 April 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
JSJohannes Schimunek
Johannes Schimunek
PSPhilipp Seidl
Philipp Seidl
KEKatarina Elez
Katarina Elez
THTim Hempel
Tim Hempel
TLTuan Le
Tuan Le
THThomas M. Hermans
Thomas M. Hermans
The COVID-19 pandemic continues to pose a substantial threat to human lives and is likely to do so for years to come. Despite the availability of vaccines, searching for efficient small-molecule drugs that are widely available, including in low- and middle-income countries, is an ongoing challenge. In this work, we report the results of a community effort, the “Billion molecules against Covid-19 challenge”, to identify small-molecule inhibitors against SARS-CoV-2 or relevant human receptors. Participating teams used a wide variety of computational methods to screen a minimum of 1 billion virtual molecules against 6 protein targets. Overall, 31 teams participated, and they suggested a total of 639,024 potentially active molecules, which were subsequently ranked to find ‘consensus compounds’. The organizing team coordinated with various contract research organizations (CROs) and collaborating institutions to synthesize and test 878 compounds for activity against proteases (Nsp5, Nsp3, TMPRSS2), nucleocapsid N, RdRP (Nsp12 domain), and (alpha) spike protein S. Overall, 27 potential inhibitors were experimentally confirmed by binding-, cleavage-, and/or viral suppression assays and are presented here. All results are freely available and can be taken further downstream without IP restrictions. Overall, we show the effectiveness of computational techniques, community efforts, and communication across research fields (i.e., protein expression and crystallography, in silico modeling, synthesis and biological assays) to accelerate the early phases of drug discovery.